ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers — Stella

Recruiting

Back to With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Singapore

National Cancer Centre Singapore, Singapore, Singapore

National University Hospital, Singapore

Key details

Phase

Early testing

Sponsor

National University Hospital, Singapore

Collaborators

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Enrollment target

~16 participants

Started

December 2024

Primary completion

December 2026

Age range

21 Years – 99 Years

Sex

Female only

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov